Ziopharm Oncology, Inc. (NASDAQ: ZIOP), is collaborating with Aldevron to secure rapid neoGMP® plasmid DNA manufacturing for Ziopharm's Sleeping Beauty construct to express TCRs for treatment of solid tumors.
Genprex, Inc. (NASDAQ: GNPX), is collaborating with Aldevron to secure GMP plasmid DNA manufacturing capacity for Genprex's Oncoprex™ gene therapy portfolio.
The manufacturing program supports upcoming clinical trials, including Oncoprex™ in combination with Tagrisso®, which has received FDA Fast Track Designation. The collaboration with Aldevron will enable full commercial scale plasmid DNA manufacturing capabilities.
Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program
Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018.
Aldevron announces presentation of "Standardized Plasmids for Viral Vector Production" at BIO International Convention
Aldevron is scheduled to present, exhibit and conduct one-on-one meetings at the Biotechnology Innovation Organization’s (BIO) International Convention, June 3 – 6, 2019, in Philadelphia. Aldevron’s James Brown, VP Corporate Development, is speaking on standardized helper plasmids for viral vector production.
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs
Cambridge, Mass., January 2, 2019 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases and Aldevron, the leading producer of custom nucleic acids, proteins, and antibodies for the biotechnology industry, announced today that they have entered into a long-term strategic relationship for the supply of plasmid DNA to fulfill Sarepta’s needs for its gene therapy clinical trials and commercial supply.
Newly manufactured plasmids will be applied in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies
Austin, Texas, Cambridge, Mass. and Fargo, N.D. – September 26, 2018 – Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex for the treatment of non-small cell lung cancer.
Aldevron and Odylia, a nonprofit organization working to develop treatments for ultra-rare ocular diseases using gene therapy, have entered into an agreement in which Aldevron is a member of Odylia.